We thank you for your interest in this summary report for the 2022 European Heart Rhythm Association Meeting in Copenhagen, Denmark. It was an exciting return to meet face-to-face again after the pandemic years, and learning, sharing and networking together in-person.
Our editorial team and peer reviewers have worked hard to bring you some of the very best content of the meeting. You will find late-breaking science, new evidence and updates on the following topics: Diagnostics and Prevention, Developments in Devices, Updates on Ablation, News on Atrial Fibrillation, and Other topics. Conduction system pacing and Pulsed field ablation were the new technologies that gained lots of atttention. Techniques in the centre of attention were artificial intelligence, remote monitoring, and screening. And last but not least, better patient characterisation and selection were key topics in numerous scientific sessions.
We hope you find our peer-reviewed summaries informative, balanced, and of help in your clinical practice.
Sincerely,
Michiel Rienstra
Biography
Michiel Rienstra, MD, PhD, MHA, is Cardiologist and Professor of Clinical Cardiology and serves as Clinical Director of the Department of Cardiology, and cardiologist at the University Medical Center Groningen, The Netherlands. He is founder of the regional network HeartNet Northern-Netherlands. Prof. Rienstra earned his medical degree at the University of Antwerp, Belgium, his PhD degree at the University of Groningen, the Netherlands, and his Master of Health Administration at Tilburg University, the Netherlands. He combines treatment of patients with arrhythmias and HF with clinic-oriented AF and HF research. His research consists of conducting investigatorinitiated clinical studies to improve AF or HF treatment (among others the RACE study group) studying the epidemiology of AF and its risk factors, uncovering the genetics of AF in part with the AFGen international consortium, and applying novel bioinformatics tools to improve AF risk prediction using biobanks of AF patients. He is fellow of the European Society of Cardiology and the American Heart Association.
Research: Orchid: 0000-0002-2581-070X, publications: https://pubmed.ncbi.nlm.nih.gov
Website: www.groningencardiology.com
Email: m.rienstra@umcg.nl
Conflict of interest statement: Consultancy fees from Medtronic, Arca Biopharma Inc, and Roche to the institution.
Posted on
Previous Article
« Benefits of SGLT2 inhibitors may extend beyond HF-associated outcomes Next Article
FDA withdraws approval for TG Therapeutics cancer treatment »
« Benefits of SGLT2 inhibitors may extend beyond HF-associated outcomes Next Article
FDA withdraws approval for TG Therapeutics cancer treatment »
Table of Contents: EHRA 2022
Featured articles
Letter from the Editor
Diagnostics and Prevention
Cardiac magnetic resonance imaging improves prediction of post-MI sudden cardiac death
AI model accurately predicts sudden cardiac death in overall population
AI model accurately discriminates between arrhythmias
Impact of AF screening on stroke prevention influenced by systolic blood pressure
Developments in Devices
Conduction system pacing potential alternative for biventricular pacing in heart failure
Left bundle branch area pacing is a feasible technique for HF and bradyarrhythmia
Focus on the efficacy of cardiac resynchronisation therapy in HF plus concomitant AF
RESET: No survival benefit of CRT-defibrillator over CRT-pacemaker in heart failure
Insertable cardiac monitors effective for AF detection in cryptogenic stroke
Updates on Ablation
First results of the POWER FAST III trial
Real-world safety results on pulsed-field ablation with pentaspline catheter
VANISH: Ablation reduces shock burden compared with anti-arrhythmic drug in ventricular tachycardia
Low AF recurrence rates after PVI using pulsed-field ablation
Pulsed-field ablation reduces neurocardiac damage versus cryoballoon ablation
Ultrasound-guided femoral venipuncture reduces complications in catheter ablation
News on Atrial Fibrillation
Sex differences revealed in AF determinants and AF progression
Early rhythm-control therapy efficacious in men and women with AF
Progression in remote app-based monitoring of atrial fibrillation
Other Topics
Benefits of SGLT2 inhibitors may extend beyond HF-associated outcomes
Related Articles
June 1, 2022
First results of the POWER FAST III trial
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com